RxDoctor Payments Data

Nelson Terzian, MD

Pediatric Urology · Tavernier, FLNPI 1780721837

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (42.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Procept Biorobotics Corporation at 58.7% of the total. Reporting peaked in 2024 at $655 and has fallen 94.8% since, to $34 in 2025.

$1,064in general payments, 2019–2025

Across 13 payments — averaging $81.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$625
  • Astellas Pharma US Inc$222
  • Johnson & Johnson$85
  • Olympus America Inc.$34
  • Valencia Technologies Corporation$34
  • Boston Scientific$30
  • plus $35 from 2 others

What the payments were for

  • Travel & lodging$45042%
  • Food & beverage$41139%
  • Education$18517%
  • Entertainment$182%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,064 in reported general payments places this provider in the 70th percentile of 39 pediatric urology providers in Florida.

See all pediatric urology providers in Florida

Medicare billing

Part B allowed, 2024
$370,976
Medicare patients
431
Services billed
123,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron76$54,285
GemtesaVibegron53$38,871
Methenamine Hippurate18$1,839
Tamsulosin Hcl85$1,452
Levofloxacin105$569
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$222$54,28576 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 39 pediatric urology providers in Florida.

Other pediatric urology in Tavernier

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →